SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Care-plan review) — Susan B. Anthony

PatientSusan B. Anthony
Date of birth1941-02-15
IdentifiersMRN HR-NI014-SYN; SSN (made up) 000-14-7302
Document date2026-09-28
AuthorHarold Pemberton, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month heart failure review. [S]

History of Present Illness

Miss Anthony returns for her six-month review. She is back to lecturing twice a month and travelling by train, and walks two miles most days. She needed as-needed furosemide twice in three months, both after long train days with restaurant meals, and her weight returned to 56 kg within a day each time. Her cough from the August bronchitis has cleared. She has had no dizziness, falls, or breathlessness except on long stair climbs. [S]

ElementDetail
Interval changeBack to full activity; bronchitis resolved
As-needed diureticTwo doses in three months, after travel days
Weight diaryStable at 56 kg
FunctionLecturing twice a month; walking two miles
NYHA classI to II

Review of Systems

SystemResultFinding
ConstitutionalNegativeWeight stable; good energy
CardiovascularNegativeNo chest pain, palpitations, orthopnea, or edema
RespiratoryNegativeCough resolved; breathless only on long climbs
NeurologicalNegativeNo dizziness on standing

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Furosemide 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-16 to 2026-06-29completedS
Furosemide 20 mg oral tablet, one tablet by mouth as needed for a weight gain of more than 1 kg in a day or 2 kg in a weekOne tablet by mouth once daily as needed for weight gainOral route2026-06-29activeS
Empagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-16activeS
Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth dailyOne-half tablet by mouth dailyOral route2026-03-30activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-09-28Body height165cmS
2026-09-28Body weight56kgS
2026-09-28Body mass index (BMI) [Ratio]20.6kg/m2S
2026-09-28Systolic blood pressure126mm[Hg]S
2026-09-28Diastolic blood pressure72mm[Hg]S
2026-09-28Heart rate70/minS
2026-09-28Respiratory rate16/minS
2026-09-28Body temperature36.6CelS
2026-09-28Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-09-28Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-09-28Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-09-28Creatinine [Mass/volume] in Serum or Plasma0.9mg/dL0.59-1.04 mg/dLNormalS
2026-09-28Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M63mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-09-28Glucose [Mass/volume] in Serum or Plasma93mg/dL70-99 mg/dLNormalS
2026-09-28Overall summary score [KCCQ-12]76{score}S

Physical Exam

Vital signs recorded on 2026-09-28; see the Vital Signs section. [S]

SystemFinding
GeneralWell
NeckJugular venous pressure 6 cm
LungsClear
HeartRegular rhythm; soft S4
ExtremitiesNo edema
Orthostatic blood pressureNo fall on standing

Problems

ProblemClinical statusVerificationCodeProvenance
Heart failure with preserved ejection fraction, NYHA class II to III at diagnosis; synthetic modern diagnosis linked to the documented 1906 heart failureactiveconfirmed I50.32S — Synthetic diagnosis confirmed by echocardiogram in the modern episode; the 1906 cause of death remains D.
Hypertensive heart disease with heart failureactiveconfirmed I11.0S — Synthetic diagnosis; no blood pressure from her lifetime is recorded in the cited sources.
Acute viral bronchitis after a head cold, resolved without antibioticsresolvedconfirmed J20.9S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBasic metabolic panelEvery 3 to 6 months when stableCompleted todayPotassium 4.6, eGFR 63
ExaminationBlood pressure, heart rate, weight, jugular venous pressure, edema, lungsEvery visitCompleted todayEuvolemic; orthostatic check normal
SurveyNYHA functional classEvery visitCompleted todayClass I to II
SurveyKCCQ-12Every 3 to 6 monthsCompleted today76, up 24 points from baseline
SurveyDepression screen (PHQ-2)PeriodicallyDuePlanned at next month's annual wellness visit
LaboratoryIron studies, lipid panel, HbA1c, TSHAnnuallyUp to dateDrawn at diagnosis in March; due again next spring
ImagingEchocardiogramOnly with unexplained clinical changeNot indicatedClinically stable
Medication safetyInfluenza vaccineEvery seasonDuePlanned at next month's annual wellness visit

Goal progress:

Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023); CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026)

Follow-up: Annual wellness visit next month. Heart failure review with laboratory tests in three to six months. Next scheduled visit 2026-10-19: subsequent annual wellness visit. [S]